Gelteq Establishes China Center of Excellence to Boost Product Development, Commercial Reach
GELS sits 42% above its 52-week low of $0.387 on light trading volume (0.1× avg).
Summary
Gelteq has established a new Center of Excellence in Guangdong Province, China, a strategic move to accelerate product development and commercial expansion. This follows recent debt financing and the start of its first clinical trial, signaling an active growth phase. The center aims to leverage China's rapidly expanding biotechnology market, which saw nearly $60 billion in cross-border out-licensing deals in Q1 2026, potentially boosting Gelteq's global capabilities and market access for its drug delivery platform.
At the time of this announcement, GELS was trading at $0.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $0.39 to $3.51. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.